Characterization of Second‐Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry

Documenti analoghi

• Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2025)
• Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2024)
• Difficult‐to‐Treat Rheumatoid Arthritis With Concomitant Yao Syndrome With Response to Dual‐Inhibitor Therapy
  di: Nawar Aljundi, et al.
  Pubblicazione: (2026)
• Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis
  di: David A. Kellner, et al.
  Pubblicazione: (2025)
• Immunosuppressive Medications and Nonserious Infections in People With Rheumatoid Arthritis: A Prospective Cohort Study
  di: Michael D. George, et al.
  Pubblicazione: (2026)